Effectiveness of anti-psychotics and related drugs in the Huntington french-speaking group cohort

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Désaméricq, Gaëlle ^a,b,c,d   Dolbeau, Guillaume ^a,b,c   Verny, Christophe ^e,f   Charles, Perrine ^c,g   Durr, Alexandra ^c   Youssov, Katia ^a,b,c,d   Simonin, Clémence ^h,i,j   Azulay, Jean Philippe ^k   Tranchant, Christine ^l,m   Goizet, Cyril ⁿ   Damier, Philippe ^f   Broussolle, Emmanuel ^o,p,q   Demonet, Jean François ^r   Morgado, Graca ^b,c,f   De Langavant, Laurent Cleret ^a,b,c,d   Macquin Mavier, Isabelle ^b,c   Bachoud Lévi, Anne Catherine ^a,b,c,d   Maison, Patrick ^a,b,c,d  

^a INSERM U955   (France)

^b FACULTÉ DE MÉDECINE   (France)

^c HENRI MONDOR HOSPITAL   (France)

^d ECOLE NORMALE SUPÉRIEURE   (France)

^e ANGERS UNIVERSITY HOSPITAL   (France)

^f INSERM   (France)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^j UNIV LILLE   (France)

^k TIMONE HOSPITAL   (France)

^l HÔPITAL DE HAUTEPIERRE   (France)

^m UNIVERSITÉ DE STRASBOURG   (France)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o UNIVERSITÉ LYON 1   (France)

^p HÔPITAL NEUROLOGIQUE   (France)

^q INSTITUT DES SCIENCES COGNITIVES   (France)

^r LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZAMIDE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; TETRABENAZINE; TIAPRIDE;

ADULT; ARTICLE; BEHAVIOR; COGNITION; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FRANCE; FUNCTIONAL STATUS; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; DISEASE COURSE; HUNTINGTON DISEASE; PATHOPHYSIOLOGY;

ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; FRANCE; HUMANS; HUNTINGTON DISEASE;

EID: 84898664322     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085430     Document Type: Article

References (30)

1. Mulrow CD, Cook DJ, Davidoff F (1997) Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 126:389-391.
2. Mulrow CD, Cook DJ, Davidoff F (1997) Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 126:389-391. (Pubitemid 47075343)
3. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:971-983.
4. Van Duijn E, Kingma EM, Van Der Mast RC (2007) Psychopathology in verified Huntington's disease gene carriers. J Neuropsychiatry Clin Neurosci 19:441-448. doi:10.1176/appi.neuropsych.19.4.441. (Pubitemid 350156103)
5. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C (2009) Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev: CD006456. doi:10.1002/14651858. CD006456.pub2.
6. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10:83-98. doi:10.1016/S1474- 4422 (10) 70245-3.
7. Venuto CS, McGarry A, Ma Q, Kieburtz K (2012) Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 27:31-41. doi:10.1002/mds.23953.
8. Orth M, Handley OJ, Schwenke C, Dunnett SB, Craufurd D, et al. (2010) Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr 2. Available: http://www.ncbi.nlm.nih.gov/pubmed/20890398. Accessed 21 February 2012.
9. Priller J, Ecker D, Landwehrmeyer B, Craufurd D (2008) A Europe-wide assessment of current medication choices in Huntington's disease. Mov Disord 23:1788. doi:10.1002/mds.22188.
10. Shoulson I (1981) Huntington disease. Neurology 31:1333-1333.
11. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group (1996). Mov Disord 11:136-142. doi:10.1002/mds.870110204. (Pubitemid 26082779)
12. WHO collaborating centre for drug statistics methodology (n. d.) WHOCC - ATC/DDD Index. Available: http://www.whocc.no/atc-ddd-index/. Accessed 21 February 2012.
13. Spreeuwenberg MD, Bartak A, Croon MA, Hagenaars JA, Busschbach JJV, et al. (2010) The multiple propensity score as control for bias in the comparison of more than two treatment arms: an introduction from a case study in mental health. Med Care 48:166-174. doi:10.1097/MLR.0b013e3181c1328f.
14. Feigin A, Kieburtz K, Bordwell K, Como P, Steinberg K, et al. (1995) Functional decline in Huntington's disease. Mov Disord 10:211-214. doi:10.1002/mds.870100213.
15. Penney JB Jr, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, et al. (1990) Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 5:93-99. doi:10.1002/mds.870050202. (Pubitemid 20166182)
16. Van Vugt JPP, Piet KKE, Vink LJ, Siesling S, Zwinderman AH, et al. (2004) Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up. Mov Disord 19:285-297. doi:10.1002/mds.10718. (Pubitemid 38961082)
17. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial (2006). Neurology 66:366-372. doi:10.1212/01.wnl. 0000198586.85250.13.
18. Frank S (2009) Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol 9:62. doi:10.1186/1471-2377-9-62.
19. Bonelli RM, Mahnert FA, Niederwieser G (2002) Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 25:263-265. (Pubitemid 35239484)
20. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, et al. (2001) Shortterm effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 14:69-72. (Pubitemid 32179139)
21. Paleacu D, Anca M, Giladi N (2002) Olanzapine in Huntington's disease. Acta Neurol Scand 105:441-444. (Pubitemid 34620570)
22. Bonelli RM, Wenning GK (2006) Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 12:2701-2720.
23. Erdemoglu AK, Boratav C (2002) Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 9:182-183. (Pubitemid 35021260)
24. Laks J, Rocha M, Capitão C, Domingues RC, Ladeia G, et al. (2004) Functional and motor response to low dose olanzapine in Huntington's disease: case report. Arq Neuropsiquiatr 62:1092-1094. doi:/S0004-282X2004000600030. (Pubitemid 40013114)
25. Quinn N, Marsden CD (1985) Tiapride in 12 Huntington's disease patients. J Neurol Neurosurg Psychiatr 48:292.
26. Bonelli RM, Wenning GK, Kapfhammer HP (2004) Huntington's disease: present treatments and future therapeutic modalities. Int Clin Psychopharmacol 19:51-62. (Pubitemid 38316763)
27. Guo X, Zhai J, Wei Q, Twamley EW, Jin H, et al. (2011) Neurocognitive effects of first- and second-generation antipsychotic drugs in early-stage schizophrenia: a naturalistic 12-month follow-up study. Neurosci Lett 503:141-146. doi:10.1016/j.neulet.2011.08.027.
28. Nance MA, Sanders G (1996) Characteristics of individuals with Huntington disease in long-term care. Movement Disorders 11:542-548. doi:10.1002/mds. 870110509. (Pubitemid 26306080)
29. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and metaanalysis. Schizophr Res 123:225-233. doi:10.1016/j.schres.2010.07.012.
30. Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358-362. (Pubitemid 27087603)